Category: Uncategorized

This Invention receives WORLD’s Prestigious GHP– GLOBAL The HEALTHCARE and PHARMACEUTICAL Award Winner in 2023, STAFFORDSHIRE, UNITED KINGDOM. Best Prognostic Diabetic Biomarker Development Company 2023 – Western Asia GHP– GLOBAL The HEALTHCARE and PHARMACEUTICAL Award Winner in 2024, STAFFORDSHIRE, UNITED KINGDOM. Prognostic Diabetic Biomarker Development Company of the Year 2024 Healthcare & Pharmaceuticals Awards – 2024 GHP– GLOBAL The HEALTHCARE and PHARMACEUTICAL Award Winner in 2025, STAFFORDSHIRE, UNITED KINGDOM. Best Emerging Innovator in Diabetes Treatment 2025 – Europe Global Excellence Awards – 2025 This Invention also … Continue reading “This invention is submitted a proposal for the LASKER AWARD 2024 and HARVARD MEDICAL SCHOOL ‘WARREN ALPERT PRIZE’ 2024 and EUROPEAN INVENTOR AWARD 2024.”

Inventor Dr. Mehmet Ali SÖYLEMEZ discovered first time, the utility of the biomarker PROCALCITONIN in DIABETES MELLITUS and DIABETIC FOOT SYNDROME. More than 50 peer reviewed* publications have followed, substantiating PROCALCITONIN as one of the most promising biomarker tools for DIABETES MELLITUS and DIABETIC FOOT SYNDROME of healthcare. Please see the patent rights for THE INVENTION EP 2626704B1 (local copy). Procalcitonin Kit and Diagnostic Device Producers and Diagnostic Companies. Procalcitonin test users  or Public –Private Medical Institutions. If you see … Continue reading “Patent Rights”

Inventor Dr. Mehmet Ali SÖYLEMEZ discovered first time, the utility of the biomarker PROCALCITONIN in DIABETES MELLITUS and DIABETIC FOOT SYNDROME. More than 50 peer reviewed* publications have followed, substantiating PROCALCITONIN as one of the most promising biomarker tools for DIABETES MELLITUS and DIABETIC FOOT SYNDROME of healthcare.      PRIMARY LOCATION:ISTANBUL-TURKEY PositionCLINICAL GENETICIST ResidencyMARMARA UNIVERSITY, SCHOOL OF MEDICINE Visitor for Medical ResearchHARVARD MEDICAL SCHOOL COUNTWAY LIBRARY OF MEDICINE Medical SchoolISTANBUL UNIVERSITY, SCHOOL OF MEDICINE Every Diabetic patient and their … Continue reading “Resume of the Inventor – Mehmet Ali Söylemez, MD”

The Invention policy is based on the following References. Inventor Dr. Mehmet Ali SÖYLEMEZ discovered first time, the utility of the biomarker PROCALCITONIN in DIABETES MELLITUS and DIABETIC FOOT SYNDROME. More than 50 peer reviewed* publications have followed, substantiating PROCALCITONIN as one of the most promising biomarker tools for DIABETES MELLITUS and DIABETIC FOOT SYNDROME of healthcare.  Diabetic foot syndrome (DFS), as defined by the World Health Organization, is an “ulceration of the foot (distally from the ankle and including … Continue reading “References”

Inventor Dr. Mehmet Ali SÖYLEMEZ discovered first time, the utility of the biomarker PROCALCITONIN in DIABETES MELLITUS and DIABETIC FOOT SYNDROME. More than 50 peer reviewed* publications have followed, substantiating PROCALCITONIN as one of the most promising biomarker tools for DIABETES MELLITUS and DIABETIC FOOT SYNDROME of healthcare. The method is useful for performing in vitro diagnosis of pancreatic diabetes mellitus and/or pancreatic diabetes mellitus complications chosen from diabetic microangiopathy, retinopathy, nephropathy, neuropathy, retinopathy, macroangiopathy and diabetic foot syndrome and/or … Continue reading “Summary”

Inventor Dr. Mehmet Ali SÖYLEMEZ discovered first time, the utility of the biomarker PROCALCITONIN in DIABETES MELLITUS and DIABETIC FOOT SYNDROME. More than 50 peer reviewed* publications have followed, substantiating PROCALCITONIN as one of the most promising biomarker tools for DIABETES MELLITUS and DIABETIC FOOT SYNDROME of healthcare. There are currently 529 million people living with diabetes mellitus. 12% of global health expenditure is spent on diabetes. Approximately 46% of people living with diabetes are doing so without a full … Continue reading “Invention Details”